Abstract: Novel 3,4-disubstituted-N-acylanilines of the formula: ##STR1## wherein R.sup.1, R.sup.2 and ring A are defined in claim 1; wherein R.sup.3 is hydrogen or alkyl of up to 4 carbon atoms, or is joined to R.sup.5 as stated below;wherein R.sup.4 is alkyl of 2 to 4 carbon atoms, or has the formula --CX.sup.1 X.sup.2 X.sup.3 wherein X.sup.1, X.sup.2 and X.sup.3, which may be the same or different, each is hydrogen, fluorine or chlorine; wherein R.sup.5 is hydrogen, hydroxy or alkoxy or acyloxy each of up to 15 carbon atoms, or is joined to R.sup.3 to form an oxycarbonyl group such that together with the ##STR2## part of the molecule it forms an oxazolidinedione group; and wherein R.sup.6 is hydrogen or halogen. These compounds possess antiandrogenic activity and are useful for the treatment of androgen dependent or prostatic diseases. Representative of the compounds is 3,4-dichloro-N-(2-hydroxy-2-p-nitrophenylpropionyl)aniline.

Abstract: The disclosure relates to novel 17,18,19,20-tetranor-prostanoic acid derivatives having prostaglandin-type properties, to a method for their manufacture, and also to pharmaceutical or veterinary compositions containing said novel derivatives and a method of inducing luteolysis in an animal host by use of said novel derivatives.